Published in Medical Letter on the CDC and FDA, March 12th, 2006
The collaboration will draw upon Optimata's biomathematical and disease modeling expertise which enables an accurate portrayal of the dynamics of disease processes and detailed predictions of drug effects. The collaboration will demonstrate how using Optimata's Virtual Patient technology can aid in shortening preclinical development time and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.